Compare DWSN & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | NVNO |
|---|---|---|
| Founded | 1952 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 16.7M |
| IPO Year | N/A | N/A |
| Metric | DWSN | NVNO |
|---|---|---|
| Price | $1.78 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.9K | ★ 956.3K |
| Earning Date | 11-12-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $64,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.08 | $0.30 |
| 52 Week High | $5.54 | $5.62 |
| Indicator | DWSN | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 31.90 |
| Support Level | $1.69 | $0.32 |
| Resistance Level | $1.87 | $0.37 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.44 | 6.24 |
Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.